Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI-360
- Development stage
- Phase 1
- Lead developer
- Suzhou Innovent Biologics
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IBI-360 is a monoclonal antibody developed by Innovent Biologics that targets Claudin 18.2 (CLDN18.2), a tight junction protein overexpressed in certain solid tumors, particularly gastrointestinal cancers. The drug is designed to induce antibody-dependent cell cytotoxicity and stimulate T lymphocytes, thereby promoting immune-mediated destruction of tumor cells. It has been investigated as both monotherapy and in combination with other agents such as sintilimab for the treatment of advanced or metastatic solid tumors, including adenocarcinoma and pancreatic cancer. Clinical development has primarily occurred in China, with phase 1 trials completed but no current reports of further development or approval[1][2][3].
- Other names
- IBI-360IBI360IBI 360
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on IBI-360.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI-360.